xAnts

Rome – Italy’s antitrust authority, the Italian Competition Authority (AGCM), has launched an investigation into Biogen and its Italian subsidiary, Biogen Italia, concerning allegations of market abuse related to a diagnostic test for the multiple sclerosis drug Tysabri (natalizumab). The investigation centers around claims that Biogen is leveraging its dominant market position to unfairly influence the market for this crucial diagnostic.

The AGCM’s inquiry follows concerns raised regarding the promotion and distribution of the test, which is considered essential for determining patient suitability for Tysabri treatment. Tysabri is a disease-modifying therapy used to treat relapsing forms of multiple sclerosis. The test helps to identify patients at risk of a rare but serious brain infection called progressive multifocal leukoencephalopathy (PML), which can occur during treatment with natalizumab.

While the specifics of the allegations remain confidential during the investigation, the AGCM’s mandate is to ensure fair competition within the Italian pharmaceutical market. Market abuse can include practices that stifle competition, restrict access, or manipulate prices. The authority has the power to impose significant fines and order corrective measures if it finds evidence of wrongdoing.

Biogen has not yet released a formal statement addressing the investigation directly, but it is expected to cooperate fully with the AGCM’s inquiries. The investigation is ongoing, and the AGCM will assess the evidence before reaching any conclusions. The outcome could have significant implications for Biogen's market practices in Italy and potentially set a precedent for similar cases involving pharmaceutical companies and diagnostic testing.

The Italian Competition Authority (AGCM) is an independent administrative body responsible for enforcing antitrust laws in Italy. It investigates and prosecutes violations of competition law, aiming to promote a level playing field for businesses and protect consumers.